At the International Plasma Protein Congress (IPPC 2026), held on 28-29 April in Milan, IPOPI actively represented the voice of people living with primary immunodeficiencies and associated conditions in key policy discussions shaping the future of plasma-derived therapies.

Through contributions from IPOPI President Martine Pergent and Executive Director Johan Prevot, we highlighted that any legislative changes need to ensure that patients have access to these life-saving therapies.

IPOPI remains committed to ensuring that evolving policies translate into real impact for people living with primary immunodeficiencies and associated conditions.